Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19

Inclusion Criteria:

• Patient is in HMC facility for low-acuity, Covid-positive patients being quarantined.
• Positive Covid test on qualitative assay used during routine care (i.e. not as part ofQ-PROTECT)
• Age at least 18

Exclusion Criteria:

• Treating physician judges patient not appropriate for study participation for anyreason
• Age <18
• Breastfeeding or pregnancy (patient-reported pregnancy status is sufficient)
• Hypersensitivity to chloroquine or HC or AZ
• History of or known QT prolongation
• EKG required before study entry and on each visit during the subject's firstseven days on pro-tocol, during the time period HC is being taken
• Baseline QTc >480 if QRS width normal; QTc >510 if QRS >120
• Known G6PD deficiency, porphyria, or retinopathy (eye exam prior to study entry)
• Known hepatic or renal disease (or abnormality on liver or renal function testing atstudy day 1)
• Low magnesium or low potassium (by testing on day 1)
• Current (pre-study) therapy with antimalarial or dapsone
• Current (pre-study) therapy with antiviral agents (e.g. oseltamivir)
• Tisdale36 score exceeding 6 as tallied below (based on ACC recommendations)*
• 1 point each: age>67, female sex, or being on loop diuretic
• 2 points each: serum potassium <3.6, QTc>449, acute myocardial infarction
• 3 points each: sepsis, heart failure, QT-prolonging drugs